LivaNova (LIVN) has drawn fresh attention after recent trading left the share price near US$75. Investors are weighing double digit annual revenue and net income growth against mixed returns across different time frames.
Recent trading tells a mixed story for LivaNova. The share price is up 25.2% year to date and the 1 year total shareholder return is 45.7%. However, a 30 day share price decline of 5.9% and a 90 day drop of 8.1% suggest momentum has cooled after a strong run.
Scan beyond LivaNova and see how other medical device players with strong fundamentals stack up in our hand picked list of list of solid balance sheet and fundamentals (25 results) .
LivaNova now trades near US$75, at a discount to both analyst targets and some intrinsic value estimates. Is that a genuine mispricing, or is the market correctly pricing in the risks?
Most Popular Narrative: 15% Undervalued
LivaNova's most followed valuation narrative points to a fair value of $89.10, above the recent close near $75, which frames the current debate around whether the discount compensates for execution and regulatory risks.
The company's clinical innovations, including strong, durable VNS study data in epilepsy and depression, launch of disruptive next-generation OSA neurostimulation (p-HGNS), and continued product upgrades (such as the Essenz platform's software upgradability), position LivaNova to capture share from the long-term shift toward minimally invasive, personalized therapies, which can drive pricing power and higher net margins.
See why 5 investors see LivaNova as 15% undervalued .
The narrative ties that $89.10 fair value back to an 8.06% discount rate, revenue growth assumptions of about 7.7% a year, and profit margins a little above 13%. It effectively asks you to judge whether those forecasts and a future P/E near 26x feel realistic for a medical device business with forecast earnings growth of 9.6% a year and a return on equity projected at 11.7%.
Result: Fair Value of $89.10 (UNDERVALUED)
Still, two pressure points could upset that 15% undervalued narrative for LivaNova: tighter reimbursement on key therapies and any regulatory or product safety setback.
Find out about the key risks to this LivaNova narrative .
Next Steps
Feel the push and pull in this LivaNova story. Use the same data behind these narratives to reach your own view by weighing the 4 key rewards and 2 important warning signs .
Looking for more investment ideas beyond LivaNova?
Do not stop your research at LivaNova. Fresh opportunities can emerge quickly, so keep a watchlist of alternatives that fit your risk and return preferences.
Use the Simply Wall St Screener to quickly surface focused sets of candidates that match the kind of portfolio you want to build.
-
Target potential mispricing by scanning a focused group of quality companies that screen as undervalued using the 27 high quality undervalued stocks .
-
Protect the downside first and concentrate on resilience by sorting through 31 resilient stocks with low risk scores that score well on stability and risk checks.
-
Get ahead of the crowd and review 20 high quality undiscovered gems before they appear on more investors' radars.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LIVN .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
